Carcinoembryonic Antigen Market Analysis by Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer) and Segment Forecasts To 2022

Table of Content

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Carcinoembryonic Antigen Industry Outlook
3.1 Market segmentation
3.2 Market size and growth prospects
3.3 Carcinoembryonic antigen - Market dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing prevalence of cancer
3.3.1.2 Increasing geriatric population
3.3.1.3 Increasing demand for minimally invasive diagnostic procedures
3.3.1.4 Growing healthcare expenditure triggering the need for an effective diagnostic procedure for cancer
3.3.1.5 Increasing usage of combination biomarkers
3.3.1.6 Usage of CEA at various stages of cancer
3.3.2 Market Restraint Analysis
3.3.2.1 Inefficiency to diagnose cancer at early stages
3.3.2.2 Presence of complicated regulatory framework
3.4 Key Opportunities Prioritized
3.5 Industry analysis - Porter’s
3.6 Carcinoembryonic Antigen - PESTEL Analysis
Chapter 4 Carcinoembryonic Antigen Application Outlook
4.1 Carcinoembryonic antigen revenue share by application, 2014 & 2022
4.2 Colorectal cancer market
4.2.1 Colorectal cancer market, 2012 - 2022 (USD Million)
4.3 Pancreatic cancer
4.3.1 Pancreatic cancer market, 2012 - 2022 (USD Million)
4.4 Ovarian cancer
4.4.1 Ovarian cancer market, 2012 - 2022 (USD Million)
4.5 Breast cancer
4.5.1 Breast cancer market, 2012 - 2022 (USD Million)
4.6 Thyroid cancer
4.6.1 Thyroid cancer market, 2012 - 2022 (USD Million)
4.7 Others
4.7.1 Others market, 2012 - 2022 (USD Million)
Chapter 5 Carcinoembryonic Antigen Regional Outlook
5.1 Carcinoembryonic antigen market share, by region, 2014 & 2022
5.2 North America
5.2.1 North America market, by application, 2012 - 2022 (USD Million)
5.2.2 U.S.
5.2.3 U.S. market, by application, 2012 - 2022 (USD Million)
5.2.4 Canada
5.2.5 Canada market, by application, 2012 - 2022 (USD Million)
5.3 Europe
5.3.1 Europe market, by application, 2012 - 2022 (USD Million)
5.3.2 Germany
5.3.3 Germany market, by application, 2012 - 2022 (USD Million)
5.3.4 France
5.3.5 France market, by application, 2012 - 2022 (USD Million)
5.3.6 Spain
5.3.7 Spain market, by application, 2012 - 2022 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific market, by application, 2012 - 2022 (USD Million)
5.4.2 Japan
5.4.3 Japan market, by application, 2012 - 2022 (USD Million)
5.4.4 China
5.4.5 China market, by application, 2012 - 2022 (USD Million)
5.4.6 India
5.4.7 India market, by application, 2012 - 2022 (USD Million)
5.5 Latin America
5.5.1 Latin America market, by application, 2012 - 2022 (USD Million)
5.5.2 Mexico
5.5.3 Mexico market, by application, 2012 - 2022 (USD Million)
5.5.4 Brazil
5.5.5 Brazil market, by application, 2012 - 2022 (USD Million)
5.6 MEA
5.6.1 MEA market, by application, 2012 - 2022 (USD Million)
5.6.2 South Africa
5.6.3 South Africa market, by application, 2012 - 2022 (USD Million)
Chapter 6 Competitive Landscape
6.1 Quest Diagnostics
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Roche Diagnostics
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Abbott Diagnostics
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 GenWay Biotech Inc.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Correlogic Systems, Inc.
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives

List of Tables

TABLE 1 Carcinoembryonic antigen - Industry summary & Critical Success Factors (CSFs)
TABLE 2 Global market, by application, 2012 - 2022 (USD Million)
TABLE 3 Global carcinoembryonic antigen market, by region, 2012 - 2022 (USD Million)
TABLE 4 Carcinoembryonic antigen - Key market driver analysis
TABLE 5 Global cancer incidences in 2012
TABLE 6 North America cancer incidences in 2012
TABLE 7 Europe cancer incidences in 2012
TABLE 8 Asia cancer incidences in 2012
TABLE 9 Africa cancer incidences in 2012
TABLE 10 Australia and New Zealand cancer incidences in 2012
TABLE 11 North America geriatric population, 2012 - 2022 (Over 60 Years) (Million)
TABLE 12 Europe geriatric population, 2012 - 2022 (Over 60 Years) (Million)
TABLE 13 Asia geriatric population, 2012 - 2022 (Over 60 Years) (Million)
TABLE 14 Latin America geriatric population, 2012 - 2022 (Over 60 Years) (Million)
TABLE 15 Africa geriatric population, 2012 - 2022 (Over 60 Years) (Million)
TABLE 16 Healthcare Expenditure, 2012
TABLE 17 Carcinoembryonic antigen - Key market restraint analysis
TABLE 18 North America market, by application, 2012 - 2022 (USD Million)
TABLE 19 U.S. carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
TABLE 20 Canada market, by application, 2012 - 2022 (USD Million)
TABLE 21 Europe market, by application, 2012 - 2022 (USD Million)
TABLE 22 Germany market, by application, 2012 - 2022 (USD Million)
TABLE 23 France market, by application, 2012 - 2022 (USD Million)
TABLE 24 Spain carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
TABLE 25 Asia Pacific market, by application, 2012 - 2022 (USD Million)
TABLE 26 Japan carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
TABLE 27 China carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
TABLE 28 India carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
表29拉丁美洲市场,通过应用程序,201年2 - 2022 (USD Million)
TABLE 30 Mexico market, by application, 2012 - 2022 (USD Million)
TABLE 31 Brazil carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
TABLE 32 MEA carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
TABLE 33 South Africa market, by application, 2012 - 2022 (USD Million)

List of Figures

FIG. 1 Carcinoembryonic antigen: Market segmentation
FIG. 2 Global Carcinoembryonic Antigen market, 2012 - 2022 (USD Million)
FIG. 3 Carcinoembryonic antigen: Market dynamics
FIG. 4 Global geriatric population, 2012 - 2022 (Million)
FIG. 5 Key opportunities prioritized
FIG. 6 Carcinoembryonic antigen market - Porter’s analysis
FIG. 7 Carcinoembryonic antigen market - PESTEL analysis
FIG. 8 Carcinoembryonic antigen revenue share by application, 2014 & 2022
FIG. 9 Colorectal cancer market, 2012 - 2022 (USD Million)
FIG. 10 Pancreatic cancer market, 2012 - 2022 (USD Million)
FIG. 11 Ovarian cancer market, 2012 - 2022 (USD Million)
FIG. 12 Breast cancer market, 2012 - 2022 (USD Million)
FIG. 13 Thyroid cancer market, 2012 - 2022 (USD Million)
FIG. 14 Others market, 2012 - 2022 (USD Million)
FIG. 15 Carcinoembryonic antigen market share, by region, 2014 & 2022
FIG. 16 North America Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 17 U.S. Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 18 Europe Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 19 Germany Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 20 France Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 21 Spain Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
图22亚太癌胚抗原标记et, 2012 - 2022 (USD Million)
FIG. 23 India Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 24 China Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 25 Japan Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 26 Latin America Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 27 Mexico Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 28 Brazil Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
FIG. 29 MEA Carcinoembryonic antigen market, 2012 - 2022 (USD Million)